Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Change in HbA1c From Randomization to Approximately 16 Weeks

Time frame · Randomization, 16 weeks

Absolute change in HbA1c from randomization to end of core phase (16 weeks) in incretin based therapy arm and insulin arm, and mean difference of change in HbA1c between the two treatment groups based on an ANOVA model using treatment (Incretin, Insulin) and the two randomization stratification factors (Disease: Cushing's disease vs Acromegaly; Baseline glycemic status: HbA1c \<7% vs HbA1c ≥ 7%) as fixed effects. For Participants who discontinued the study or required rescue treatment before the time of assessing the primary endpoint, the last HbA1c assessment collected 8 weeks (56 days) after randomization (and prior to or on the date of start of rescue treatment) was carried forward. If the participant discontinued the study or used rescue treatment within 8 weeks after randomization, it was considered missing.

Change in HbA1c From Randomization (R) Over Time Per Randomized Arm

Time frame · Randomization (R), Week (W) 4 post R, W 8 post R, W 16 post R, end of Core phase (up to week 16 post R)

Absolute change in HbA1c overtime from randomization (i.e. start of randomized antidiabetic treatment) to end of core phase per randomized arm

Change in FPG (Fasting Plasma Glucose) From Randomization Until End of Core Phase

Time frame · Randomization, R(randomization) Week 2, R-Week 4, R-Week 6, R-Week 8, R-Week 10, R-Week 12, R-Week 14, R-Week 16, end of Core phase

Absolute change in fasting glucose overtime from randomization (i.e. start of randomized antidiabetic treatment) to end of core phase per randomized arm

Percentage of Participants in the Incretin-based Arm Who Required Anti-diabetic Rescue Therapy With Insulin

Time frame · Randomization to up to 16 weeks

The percentage of participants who received anti-diabetic rescue therapy in incretin based therapy is summarized.

Absolute Change in HbA1c From Baseline to End of Core Phase

Time frame · Baseline, up to 32 weeks (end of Core phase)

Absolute change in HbA1c from baseline to end of core phase in the incretin based therapy arm and the insulin arm

Absolute Change in FPG From Baseline to End of Core Phase

Time frame · Baseline, Up to 32 weeks (end of Core Phase)

Absolute change in FPG from baseline to end of core phase in the incretin based therapy arm and the insulin arm.

Percentage of Participants With ≤ 0.3% HbA1c Increase to End of Core Phase

Time frame · Randomization, up to 16 weeks

Percentage of participants with ≤ 0.3% HbA1c increase in the incretin based therapy arm and the insulin arm.